Controversial blood testing organization Theranos is going on the offensive in the wake of an apparent second regulatory rebuke and finding itself at the center of slight controversy involving the presidential bid of Hillary Clinton. The company announced the expansion of medical advisory board to address what a spokesperson said was its key problem: management and leadership oversight. Against this background the $9 billion medical start-up clarified its involvement in a recent fund raising event involving Elizabeth Homes and Chelsea Clinton. Theranos new offensive: We never intended to host the Clinton event, just one friend helping another Theranos never planned on using…
Theranos Offensive: Advisory Board Announced, Claims They Never Intended To Host Clinton Fundraiser
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.